Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Nanvuranlat, an L-type amino acid transporter (LAT1) inhibitor for patients with pretreated advanced refractory biliary tract cancer (BTC): Primary endpoint results of a randomized, double-blind, placebo-controlled phase 2 study.
Authors
Junji Furuse
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan;
Junji Furuse , Masafumi Ikeda , Makoto Ueno , Masayuki Furukawa , Chigusa Morizane , Tetsuo Takehara , Tomohiro Nishina , Akiko Todaka , Naohiro Okano , Kazuo Hara , Yousuke Nakai , Kazuyoshi Ohkawa , Takashi Sasaki , Kazuya Sugimori , Naoyuki Yokoyama , Kouji Yamamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN000034080
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 494)
DOI
10.1200/JCO.2023.41.4_suppl.494
Abstract #
494
Poster Bd #
A3
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Treatment outcomes by stratifying the N-acetyl transferase 2 phenotype in pre-treated patients with advanced refractory biliary tract cancer treated with nanvuranlat, an L-type amino acid transporter inhibitor: An ad-hoc analysis of a randomized, double-blind, placebo-controlled phase 2 study.
First Author: Naohiro Okano
Poster
2019 ASCO Annual Meeting
A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
First Author: Richard D. Kim
Poster
2019 ASCO Annual Meeting
Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).
First Author: Dae Won Kim
Poster
2014 ASCO Annual Meeting
Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.
First Author: Yvonne H. Yeung